Is HCP Plastene overvalued or undervalued?

As of 3 September 2025, HCP Plastene's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, particularly given its favorable ratios such as a PE Ratio of 14.48, an EV to EBITDA of 9.63, and a PEG Ratio of 0.02. These metrics suggest that HCP Plastene is trading at a discount compared to its peers.
In comparison to notable competitors, Garware Hi Tech is deemed expensive with a PE of 20.7, while AGI Greenpac is classified as very attractive with a PE of 16.39. HCP Plastene's strong ROCE of 11.22% and ROE of 15.93% further reinforce its valuation appeal. Despite recent stock performance showing a decline against the Sensex over the past month, the long-term returns indicate a significant outperformance, particularly over the last five years, where the stock has surged by 4089.74%.